CryoLife announced on 10 July that it has received US Food and Drug Administration (FDA) premarket approval for its new Sologrip minimally invasive laser fibre-optic delivery system.
The Sologrip delivery system is a single-use, disposable handset designed for use with the company’s cardiogenesis transmyocardial revascularisation (TMR) system.
“We are pleased to receive FDA approval for our updated Sologrip handset. We believe it will be well received by our customers and we look forward to continuing our efforts to increase adoption of this important treatment option for patients with angina,” said Steven G Anderson, chairman, president and CEO of CryoLife.
